Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
70.34(c) 72.01(c) 71.67(c) 71.22(c) 73.61(c) Last
932 000 934 395 903 720 592 399 864 227 Volume
-1.50% +2.37% -0.47% -0.63% +3.36% Change
More quotes
Financials (USD)
Sales 2018 644 M
EBIT 2018 -231 M
Net income 2018 -164 M
Finance 2018 186 M
Yield 2018 -
Sales 2019 865 M
EBIT 2019 -105 M
Net income 2019 -94,0 M
Finance 2019 295 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 18,2x
EV / Sales2019 13,4x
Capitalization 11 878 M
More Financials
Company
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
01/11SEATTLE GENETICS : UW team builds protein that avoids IL-2 toxicities, forms Neo..
AQ
01/10SEATTLE GENETICS : Announces Publication of North American Subgroup Data from EC..
AQ
01/09SEATTLE GENETICS : Announces Publication of North American Subgroup Data from EC..
BU
2018SEATTLE GENETICS : to Present at the J.P. Morgan Healthcare Conference
BU
2018SEATTLE GENETICS : and Takeda Present Positive Data from Phase 3 ECHELON-2 Clini..
AQ
2018SEATTLE GENETICS : and Takeda report positive data from ECHELON-2 trial
AQ
2018SEATTLE GENETICS : rolls into latest Adcetris launch with double survival win
AQ
2018SEATTLE GENETICS : and Takeda Present Positive Data from Phase 3 ECHELON-2 Clini..
AQ
2018Weekend ASH presentations hint at future of BCMA CARs
AQ
2018SEATTLE GENETICS : and Takeda Present Positive Data from Phase 3 ECHELON-2 Clini..
BU
More news
Analyst Recommendations on SEATTLE GENETICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 80,4 $
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Srinivas Akkaraju Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.29.92%11 878
IQVIA HOLDINGS INC9.49%25 444
CELLTRION, INC.--.--%22 863
LONZA GROUP8.95%20 746
INCYTE CORPORATION23.32%16 688
EXACT SCIENCES CORPORATION24.88%9 685